Affirmed Therapeutics BV (NASDAQ:AFMD) shares traded up 1.9% on Monday . The company traded as high as $2.78 and last traded at $2.67, with a volume of 52,117 shares changing hands. The stock had previously closed at $2.62.

A number of research analysts have weighed in on the company. Jefferies Group reduced their target price on Affirmed Therapeutics BV from $5.00 to $4.00 and set a “hold” rating for the company in a report on Thursday, May 19th. BMO Capital Markets assumed coverage on Affirmed Therapeutics BV in a report on Monday, April 11th. They set an “outperform” rating and a $7.00 target price for the company. Leerink Swann lowered Affirmed Therapeutics BV from an “outperform” rating to a “market perform” rating in a report on Thursday, May 19th. Finally, Wells Fargo & Co. reaffirmed a “buy” rating on shares of Affirmed Therapeutics BV in a report on Wednesday, May 18th. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Affirmed Therapeutics BV currently has an average rating of “Buy” and a consensus price target of $9.46.

The company has a 50-day moving average of $2.82 and a 200 day moving average of $3.47. The firm’s market capitalization is $98.16 million.

Affirmed Therapeutics BV (NASDAQ:AFMD) last announced its earnings results on Wednesday, May 18th. The biopharmaceutical company reported ($0.25) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.17) by $0.08. The firm earned $1.90 million during the quarter, compared to analysts’ expectations of $1.88 million. Affirmed Therapeutics BV’s revenue was down 24.0% on a year-over-year basis. On average, equities research analysts forecast that Affirmed Therapeutics BV will post ($1.06) EPS for the current fiscal year.

Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company’s product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body’s own immune system to fight tumor cells.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.